Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

OCGN

Ocugen Inc

Feb 13 • 04:00PM ET

1.41

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX NVAX INO VXRT SAGE MCRB ADMA VTVT

| Held by: VTI VXF KOMP ITOT VHT IDNA MOON

Index	-	P/E	-	EPS (ttm)	-0.22	Insider Own	2.59%	Shs Outstand	327.89M	Perf Week	6.02%
Market Cap	462.32M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	319.40M	Perf Month	-25.00%
Enterprise Value	462.72M	PEG	-	EPS next Q	-0.06	Inst Own	23.38%	Short Float	14.80%	Perf Quarter	5.22%
Income	-64.02M	P/S	86.09	EPS this Y	-14.38%	Inst Trans	6.86%	Short Ratio	10.59	Perf Half Y	36.89%
Sales	5.37M	P/B	124.67	EPS next Y	-3.07%	ROA	-107.12%	Short Interest	47.28M	Perf YTD	4.44%
Book/sh	0.01	P/C	14.20	EPS next 5Y	44.07%	ROE	-289.93%	52W High	1.96 -28.06%	Perf Year	100.65%
Cash/sh	0.10	P/FCF	-	EPS past 3/5Y	12.68% 32.82%	ROIC	-179.63%	52W Low	0.51 173.79%	Perf 3Y	27.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	36.98%	Volatility	6.40% 7.30%	Perf 5Y	-86.28%
Dividend TTM	-	EV/Sales	86.17	EPS Y/Y TTM	-23.34%	Oper. Margin	-1112.87%	ATR (14)	0.11	Perf 10Y	-99.11%
Dividend Ex-Date	-	Quick Ratio	1.85	Sales Y/Y TTM	14.26%	Profit Margin	-1192.22%	RSI (14)	45.64	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.85	EPS Q/Q	-41.63%	SMA20	-5.65%	Beta	2.80	Target Price	9.00
Payout	-	Debt/Eq	9.34	Sales Q/Q	54.23%	SMA50	-3.48%	Rel Volume	0.36	Prev Close	1.41
Employees	95	LT Debt/Eq	9.10	Earnings	Nov 05 BMO	SMA200	14.69%	Avg Volume	4.47M	Price	1.41
IPO	Dec 03, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-20.00% 218.55%	Trades		Volume	1,623,092	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-24	Initiated	Maxim Group	Buy	$4
Mar-01-23	Upgrade	Chardan Capital Markets	Neutral → Buy	$3.50
Aug-23-22	Initiated	Mizuho	Buy	$5
Jun-15-22	Resumed	ROTH Capital	Buy	$8
Jun-02-22	Initiated	Cantor Fitzgerald	Overweight	$4.50
Jul-26-21	Initiated	Noble Capital Markets	Outperform
Jun-11-21	Downgrade	ROTH Capital	Buy → Neutral	$10 → $6
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$0.70 → $13
Feb-04-21	Upgrade	H.C. Wainwright	Neutral → Buy	$4.50

Feb-13-26 08:20AM	Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-09-26 07:02AM	Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer (GlobeNewswire)
Jan-23-26 08:00AM	Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock (GlobeNewswire)
Jan-21-26 04:37PM	Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering (Benzinga) -10.78% +10.74%
08:32AM	Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock (GlobeNewswire)
12:07PM	Loading…
Jan-16-26 12:07PM	Ocugen Stock Is Surging Today: What's Driving The Action? (Benzinga)
Jan-15-26 01:15PM	Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage (Benzinga) -13.83%
12:30PM	OS Therapies Bone Cancer Trial Data Strengthens FDA Case (Benzinga)
08:15AM	Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Jan-14-26 08:19AM	Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last? (Zacks)
Jan-13-26 07:00AM	Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data (GlobeNewswire) +7.30%
Jan-12-26 06:30AM	Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy (GlobeNewswire) +18.67%
Jan-09-26 07:02AM	Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference (GlobeNewswire)
Dec-29-25 09:53AM	Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks) +7.25%
09:20AM	Loading…
Dec-10-25 09:20AM	Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit (GlobeNewswire)
Nov-20-25 07:02AM	Ocugen CEO to Present at NobleCon21-Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference (GlobeNewswire)
Nov-09-25 08:00PM	Ocugen Inc (OCGN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-05-25 10:55AM	Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
09:49AM	Ocugen: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Ocugen Provides Business Update with Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-23-25 07:30AM	Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-02-25 07:30AM	Ocugen to Present at Industry and Investor Conferences in October 2025 (GlobeNewswire) +5.36%
Sep-15-25 07:04PM	Why Ocugen Stock Zoomed 12% Higher Today (Motley Fool) +12.15%
06:03AM	Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea (GlobeNewswire)
Sep-02-25 07:02AM	Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 (GlobeNewswire)
Aug-26-25 12:00PM	Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-25 06:27AM	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST-Modifier Gene Therapy for Stargardt Disease (GlobeNewswire)
Aug-12-25 03:45PM	Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire) +5.03%
Aug-08-25 05:03PM	Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire)
03:07AM	Loading…
Aug-02-25 03:07AM	Ocugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Aug-01-25 09:35AM	Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:33AM	Ocugen: Q2 Earnings Snapshot (Associated Press Finance)
08:25AM	Ocugen Provides Business Update with Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-21-25 07:30AM	Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team (GlobeNewswire)
07:17AM	Ocugen doses first subject in trial of modifier gene therapy candidate (Clinical Trials Arena)
Jul-18-25 07:02AM	Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease (GlobeNewswire)
Jul-17-25 06:30AM	Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-24-25 01:07PM	Carisma Therapeutics, OrthoCellix enter definitive merger agreement (TipRanks) +5.49%
Jun-23-25 07:30AM	Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases (GlobeNewswire) -7.44%
Jun-17-25 07:49AM	FDA clears Ocugens IND amendment for trial of Stargardt disease treatment (Clinical Trials Arena) -6.03%
Jun-16-25 07:02AM	Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease (GlobeNewswire)
Jun-11-25 07:30AM	Ocugen To Present at BIO International Convention 2025 (GlobeNewswire)
Jun-05-25 07:02AM	Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea (GlobeNewswire) +7.41%
May-27-25 07:02AM	Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease (GlobeNewswire)
May-10-25 03:04AM	Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... (GuruFocus.com)
May-09-25 08:07AM	Ocugen: Q1 Earnings Snapshot (Associated Press Finance)
08:01AM	Ocugen Provides Business Update with First Quarter 2025 Financial Results (GlobeNewswire)
May-02-25 08:00AM	Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 07:30AM	Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress (GlobeNewswire)
Apr-16-25 10:01AM	Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? (Insider Monkey) -6.53%
Apr-08-25 08:02AM	Ocugen to Present at the 2025 Cell & Gene Meeting on the Med (GlobeNewswire) -10.17%
Mar-26-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Mar-19-25 06:18AM	Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 (Clinical Trials Arena) +6.31%
Mar-18-25 08:02AM	Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200 a Novel Fusion Protein for Diabetic Macular Edema (GlobeNewswire) -9.83%
Mar-06-25 02:07AM	Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com) +9.96%
Mar-05-25 11:48PM	Q4 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
01:15PM	Ocugen (OCGN) Q4 2024 Earnings Call Transcript (Motley Fool)
07:21AM	Ocugen: Q4 Earnings Snapshot (Associated Press Finance)
07:02AM	Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 09:00AM	Ocugen Announces Positive Opinion of EMAs Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease (GlobeNewswire) -7.15%
08:26AM	Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN) (GlobeNewswire)
Feb-27-25 08:46AM	Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease (GlobeNewswire)
Feb-24-25 05:14PM	Grabar Law Office Is Investigating Claims On Behalf Of Long-Term Shareholders Of Atkore Inc. (NYSE: ATKR); Crocs, Inc. (NASDAQ: CROX); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN) (GlobeNewswire) -7.35%
Feb-21-25 08:00AM	Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 05:41PM	Why Ocugen (OCGN) Is Advancing Today (Insider Monkey) +6.47%
Feb-12-25 07:42AM	Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410-a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Feb-03-25 06:30AM	Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa (GlobeNewswire)
Jan-27-25 06:30AM	Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 (GlobeNewswire) -6.27%
Jan-17-25 05:31AM	Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment (Clinical Trials Arena)
Jan-16-25 07:30AM	Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200 a Novel Integrin-Targeting Biologic for Diabetic Macular Edema (GlobeNewswire)
Jan-13-25 06:30AM	Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 A Novel Modifier Gene Therapy for Retinitis Pigmentosa (GlobeNewswire)
Dec-19-24 06:38AM	Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Dec-11-24 07:02AM	Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit (GlobeNewswire)
Nov-27-24 07:09AM	Ocugen CEO to Present at NobleCon20 Noble Capital Markets' 20th Annual Emerging Growth Equity Conference (GlobeNewswire) +6.74%
Nov-20-24 07:30AM	Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease (GlobeNewswire) +5.14%
Nov-19-24 07:02AM	Ocugen Announces Compelling Preliminary Data for OCU410 a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Nov-14-24 04:40PM	Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.14%
03:32PM	Ocugen: Q3 Earnings Snapshot (Associated Press Finance)
Nov-09-24 02:14AM	Q3 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-08-24 11:15AM	Ocugen (OCGN) Q3 2024 Earnings Call Transcript (Motley Fool) -8.69%
06:45AM	Ocugen Provides Business Update with Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-07-24 06:30AM	Ocugen Secures $30 Million in Debt Funding (GlobeNewswire) +8.88%
Oct-28-24 06:30AM	Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 (GlobeNewswire) +9.24%
Oct-22-24 07:02AM	Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease (GlobeNewswire)
Oct-17-24 07:30AM	Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition of Shares in Ocugen Inc (GuruFocus.com)
Oct-10-24 07:00AM	Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-09-24 05:35PM	Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
06:30AM	Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial (GlobeNewswire)
Oct-02-24 06:30AM	Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-24-24 07:30AM	Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -6.13%
Sep-09-24 06:30AM	Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop (GlobeNewswire) +9.65%
Sep-05-24 07:00AM	Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit (GlobeNewswire)
Sep-03-24 07:30AM	Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.92%
Aug-28-24 06:30AM	Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST A Modifier Gene Therapy (GlobeNewswire)
Aug-26-24 07:02AM	Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication (GlobeNewswire)
Aug-08-24 10:49PM	Q2 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents) +8.47%
05:30PM	Ocugen (OCGN) Q2 2024 Earnings Call Transcript (Motley Fool)

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARNA C. WHITTINGTON	Director	Jul 09 '25	Proposed Sale	1.10	112,205	122,887		Jul 09 04:07 PM
PRABHAVATHI FERNANDES	Director	Jun 11 '25	Proposed Sale	1.17	146,705	171,029		Jun 11 05:46 PM

Open in Screener

ACVA

ACV Auctions Inc

Feb 13 • 04:00PM ET

6.61

+0.10 1.54 %

Consumer Cyclical • Auto & Truck Dealerships • USA • NYSE

Peers: CPRT OPLN LAD CVNA AN ABG VRM GPI TRUE PAG

| Held by: VTI VB IWM VBK VXF IWO VTWO SCHA FESM DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.43	Insider Own	5.20%	Shs Outstand	172.17M	Perf Week	-10.31%
Market Cap	1.14B	Forward P/E	29.12	EPS next Y	0.23	Insider Trans	13.52%	Shs Float	163.22M	Perf Month	-25.23%
Enterprise Value	1.04B	PEG	0.37	EPS next Q	-0.01	Inst Own	96.59%	Short Float	6.69%	Perf Quarter	20.40%
Income	-72.72M	P/S	1.55	EPS this Y	140.02%	Inst Trans	-2.03%	Short Ratio	3.76	Perf Half Y	-41.45%
Sales	735.48M	P/B	2.62	EPS next Y	35.03%	ROA	-6.61%	Short Interest	10.91M	Perf YTD	-17.58%
Book/sh	2.52	P/C	3.60	EPS next 5Y	77.90%	ROE	-16.33%	52W High	22.09 -70.08%	Perf Year	-69.38%
Cash/sh	1.84	P/FCF	14.25	EPS past 3/5Y	1.17% 0.70%	ROIC	-11.11%	52W Low	4.95 33.54%	Perf 3Y	-35.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	21.14% 42.92%	Gross Margin	47.49%	Volatility	7.42% 5.32%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.42	EPS Y/Y TTM	8.46%	Oper. Margin	-9.42%	ATR (14)	0.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.62	Sales Y/Y TTM	23.40%	Profit Margin	-9.89%	RSI (14)	27.93	Recom	1.93
Dividend Gr. 3/5Y	- -	Current Ratio	1.62	EPS Q/Q	-47.67%	SMA20	-14.95%	Beta	1.65	Target Price	10.71
Payout	-	Debt/Eq	0.51	Sales Q/Q	16.48%	SMA50	-18.04%	Rel Volume	0.78	Prev Close	6.51
Employees	2900	LT Debt/Eq	0.51	Earnings	Feb 23 AMC	SMA200	-41.50%	Avg Volume	2.90M	Price	6.61
IPO	Mar 24, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.50% -0.17%	Trades		Volume	2,248,078	Change	1.54%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-25	Downgrade	Jefferies	Buy → Hold	$9
Nov-12-25	Initiated	Barclays	Equal Weight	$6
Nov-06-25	Downgrade	BofA Securities	Buy → Underperform	$6
Nov-06-25	Downgrade	Barrington Research	Outperform → Mkt Perform
Aug-12-25	Reiterated	Needham	Buy	$25 → $16
Mar-20-25	Upgrade	Piper Sandler	Neutral → Overweight	$18 → $20
Mar-12-25	Upgrade	BofA Securities	Neutral → Buy	$22 → $20
Jan-22-25	Initiated	Stephens	Equal-Weight	$20.50
Sep-27-24	Resumed	Raymond James	Mkt Perform	$22
Jun-10-24	Upgrade	JP Morgan	Neutral → Overweight	$21
Jan-10-24	Upgrade	Northcoast	Neutral → Buy	$22
Jul-20-23	Initiated	B. Riley Securities	Buy	$23
Jul-13-23	Downgrade	JP Morgan	Overweight → Neutral	$17
Feb-16-23	Downgrade	Piper Sandler	Overweight → Neutral	$11
Jun-30-22	Resumed	JMP Securities	Mkt Outperform
Jun-10-22	Initiated	Barrington Research	Outperform	$18
Apr-20-22	Resumed	Citigroup	Buy	$20
Mar-02-22	Upgrade	Stephens	Equal-Weight → Overweight	$17 → $19
Mar-01-22	Initiated	Needham	Buy	$20
Jan-07-22	Initiated	Goldman	Buy	$26

Show Previous Ratings

Feb-02-26 12:08PM	ACV Demonstrates VIPER, AI-Powered Inspection Towers, at the 2026 National Automobile Dealers Association Conference (Business Wire)
Jan-26-26 04:05PM	ACV to Report Fourth Quarter 2025 Financial Results on February 23, 2026 (Business Wire)
Jan-15-26 11:39PM	3 Cash-Producing Stocks with Questionable Fundamentals (StockStory)
Jan-06-26 08:12AM	TimesSquare Capital U.S. Small Cap Growth Strategy's Stand on ACV Auctions (ACVA) (Insider Monkey)
Dec-31-25 05:44AM	Small-Caps Set for Upside: Goldman Sachs Suggests 2 Small-Cap Stocks for 2026 (TipRanks)
11:02PM	Loading…
Dec-23-25 11:02PM	ACV Auctions (ACVA): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Dec-21-25 11:35PM	1 Volatile Stock for Long-Term Investors and 2 Facing Headwinds (StockStory)
Dec-18-25 11:31PM	3 Small-Cap Stocks That Fall Short (StockStory)
Dec-05-25 04:57PM	ACV Auctions Inc. (ACVA): A Bull Case Theory (Insider Monkey)
Nov-24-25 06:18AM	1 Cash-Producing Stock to Own for Decades and 2 Facing Headwinds (StockStory) +5.48%
Nov-20-25 11:37PM	3 Stocks Under $10 with Warning Signs (StockStory)
Nov-18-25 09:45AM	Carl Icahn Makes Another Huge Insider Purchase (24/7 Wall St.)
Nov-17-25 11:31PM	1 Russell 2000 Stock to Consider Right Now and 2 Facing Headwinds (StockStory)
02:26PM	ACV Showcases AI-Powered Data Solutions at Used Car Week 2025 (Business Wire)
02:10PM	Why Are ACV Auctions (ACVA) Shares Soaring Today (StockStory)
10:33PM	Loading…
Nov-13-25 10:33PM	Spotting Winners: ACV Auctions (NYSE:ACVA) And Online Marketplace Stocks In Q3 (StockStory) +16.03%
12:05PM	Why Is ACV Auctions (ACVA) Stock Rocketing Higher Today (StockStory)
Nov-12-25 12:33AM	The Top 5 Analyst Questions From ACV Auctions's Q3 Earnings Call (StockStory)
Nov-06-25 01:56PM	Why ACV Auctions (ACVA) Shares Are Plunging Today (StockStory) -37.55%
09:16AM	ACVA Q3 Deep Dive: Weak Guidance, Macroeconomic Uncertainty, and Margin Pressures Weigh on Outlook (StockStory)
12:11AM	ACV Auctions Inc (ACVA) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
Nov-05-25 06:20PM	ACV Auctions Inc. (ACVA) Meets Q3 Earnings Estimates (Zacks) -8.94%
05:02PM	ACV Auctions (NYSE:ACVA) Reports Q3 In Line With Expectations But Stock Drops 13.4% (StockStory)
04:05PM	ACV Announces Third Quarter 2025 Results (Business Wire)
Nov-04-25 01:24PM	Cipher Mining Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Fall (Zacks)
07:56AM	Earnings To Watch: ACV Auctions Inc (ACVA) Reports Q3 2025 Result (GuruFocus.com)
Nov-03-25 10:18PM	ACV Auctions Earnings: What To Look For From ACVA (StockStory)
Oct-27-25 12:01AM	3 Reasons ACVA is Risky and 1 Stock to Buy Instead (StockStory)
Oct-26-25 06:16AM	Needham Lowers ACV Auctions (ACVA) Price Target to $14, Maintains Buy Rating (Insider Monkey)
Oct-20-25 05:07PM	ACV to Report Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) +5.94% +6.16%
12:34AM	Loading…
12:34AM	3 Unprofitable Stocks We Approach with Caution (StockStory)
Oct-07-25 01:05PM	Why ACV Auctions (ACVA) Shares Are Sliding Today (StockStory)
Sep-19-25 12:39AM	1 Stock Under $50 to Target This Week and 2 Facing Headwinds (StockStory)
Sep-18-25 12:34AM	1 Oversold Stock Set for a Comeback and 2 We Question (StockStory)
Sep-12-25 05:22PM	Why ACV Auctions Stock Dived by Almost 15% This Week (Motley Fool)
Sep-10-25 03:11PM	Why ACV Auctions (ACVA) Shares Are Sliding Today (StockStory) -5.01%
Sep-09-25 12:31AM	3 Russell 2000 Stocks with Questionable Fundamentals (StockStory)
Sep-08-25 02:26PM	Why ACV Auctions (ACVA) Stock Is Falling Today (StockStory) -5.08%
Aug-27-25 04:05PM	ACV to Participate in Citi's 2025 Global TMT Conference (Business Wire)
Aug-21-25 11:34PM	Unpacking Q2 Earnings: ACV Auctions (NYSE:ACVA) In The Context Of Other Online Marketplace Stocks (StockStory) +5.93%
Aug-20-25 12:36AM	1 Growth Stock Set to Flourishand 2 We Avoid (StockStory)
Aug-19-25 10:36AM	ACV Expands Its No Reserve Sale to Four Days a Week-Driving 10+ Bidders per Car and More Activity on Every Unit (GlobeNewswire)
Aug-18-25 01:32AM	5 Revealing Analyst Questions From ACV Auctions's Q2 Earnings Call (StockStory)
Aug-13-25 05:25PM	ACV Auctions, eBay, and Upwork Stocks Trade Up, What You Need To Know (StockStory)
12:50PM	ACV Auctions (ACVA) Nosedives on Lower 2025 Revenue Outlook (Insider Monkey)
Aug-12-25 03:46PM	Why ACV Auctions (ACVA) Stock Is Down Today (StockStory) -16.33%
09:15AM	ACVA Q2 Deep Dive: Margin Progress and Product Expansion Amid Market Headwinds (StockStory)
03:08AM	ACV Auctions Inc (ACVA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
Aug-11-25 06:55PM	ACV Auctions Inc. (ACVA) Matches Q2 Earnings Estimates (Zacks)
04:18PM	ACV Auctions (NYSE:ACVA) Reports Sales Below Analyst Estimates In Q2 Earnings, Stock Drops (StockStory)
04:05PM	ACV Announces Second Quarter 2025 Results (GlobeNewswire)
Aug-09-25 11:01PM	Earnings To Watch: ACV Auctions (ACVA) Reports Q2 Results Tomorrow (StockStory)
Aug-08-25 09:20AM	ACV Auctions Inc (ACVA) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-07-25 10:31AM	US Vehicle Auction Market Trends 2025-2030 Featuring Openlane, Copart, ACV, RB Global, E Automotive, eBay, COX Automotive, Capital, Cars & Bids, A Better Bid Car, AutoBidMaster, Barrett-Jackson (GlobeNewswire)
Aug-04-25 10:00AM	ACV Auctions Inc. (ACVA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-22-25 04:30PM	Figmas Auction-Like IPO Set Up to Capitalize on Strong Demand (Bloomberg)
Jul-21-25 04:05PM	ACV to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-17-25 12:31AM	1 Russell 2000 Stock to Own for Decades and 2 to Steer Clear Of (StockStory)
Jul-14-25 12:36AM	3 Small-Cap Stocks with Mounting Challenges (StockStory)
Jul-01-25 12:32AM	3 Stocks Under $50 Walking a Fine Line (StockStory)
Jun-30-25 08:41AM	The 5 Most Interesting Analyst Questions From ACV Auctions's Q1 Earnings Call (StockStory)
Jun-11-25 06:56AM	ACVA Q1 Earnings Call: Product Innovation and Market Share Drive Growth Amid Industry Headwinds (StockStory)
Jun-02-25 12:03AM	3 Reasons ACVA is Risky and 1 Stock to Buy Instead (StockStory)
May-23-25 08:10AM	Copart's Q3 Earnings In Line With Estimates But Sales Miss (Zacks)
May-21-25 11:33PM	Unpacking Q1 Earnings: ACV Auctions (NYSE:ACVA) In The Context Of Other Online Marketplace Stocks (StockStory)
May-14-25 10:05AM	ACV's Latest Digital Roundtable to Explore Smarter Strategies for Sourcing Vehicles from Consumers (GlobeNewswire)
May-08-25 10:28AM	Q1 2025 ACV Auctions Inc Earnings Call (Thomson Reuters StreetEvents)
May-07-25 05:55PM	ACV Auctions Inc. (ACVA) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:05PM	ACV Announces First Quarter 2025 Results (GlobeNewswire)
May-05-25 04:05PM	ACV to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-02-25 12:37AM	1 Cash-Producing Stock to Keep an Eye On and 2 to Ignore (StockStory)
Apr-27-25 01:08PM	1 Russell 2000 Stock on Our Watchlist and 2 to Steer Clear Of (StockStory)
Apr-23-25 04:05PM	ACV to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-01-25 05:14AM	Q4 Rundown: ACV Auctions (NYSE:ACVA) Vs Other Online Marketplace Stocks (StockStory)
Mar-22-25 05:58PM	Is ACV Auctions Inc. (ACVA) The High Growth Low Debt Stock to Invest in Now? (InsiderMonkey)
Mar-20-25 12:49PM	Piper Sandler sees used car dealership as tariff-proof play (SeekingAlpha) +7.39%
08:38AM	Piper Sandler favors used vehicle technology stocks Carvana, ACV Auctions (Investing.com)
Mar-19-25 05:06AM	Q4 Earnings Outperformers: Robinhood (NASDAQ:HOOD) And The Rest Of The Consumer Internet Stocks (StockStory)
Mar-17-25 03:49AM	Why ACV Auctions (ACVA) Is Plunging in 2025? (Insider Monkey)
Mar-12-25 09:02AM	2 Small-Cap Stocks with Solid Fundamentals and 1 to Turn Down (StockStory)
Mar-11-25 08:00AM	ACV Announces Transfer of Listing of Common Stock to the New York Stock Exchange (GlobeNewswire) +5.19%
Mar-08-25 05:47PM	Is ACV Auctions Inc. (ACVA) the Fastest Growing Auto Stock to Invest In Now? (Insider Monkey)
Feb-24-25 08:07AM	Shutterstock (SSTK) Reports Earnings Tomorrow: What To Expect (StockStory)
Feb-23-25 08:04AM	EverQuote (EVER) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
Feb-21-25 04:30PM	Carvana Pulls The Emergency Brake As Online Car Sellers Collapse (Investor's Business Daily) -5.41%
12:00PM	Three Online Car Sellers Sink On Weak Guidance, Led By Carvana (Investor's Business Daily)
12:00PM	Three Online Car Retailers Sink On Weak Guidance, Led By Carvana (Investor's Business Daily)
07:26AM	Why ACV Auctions Inc. (ACVA) Crashed on Thursday (Insider Monkey)
Feb-20-25 04:11PM	Carvana Earnings Surge 498% But Key Metric Weakens; CarGurus Due (Investor's Business Daily) -9.98%
01:50PM	Why ACV Auctions (ACVA) Stock Is Down Today (StockStory)
08:03AM	Q4 2024 ACV Auctions Inc Earnings Call (Thomson Reuters StreetEvents)
02:13AM	ACV Auctions Inc (ACVA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Feb-19-25 06:00PM	ACV Auctions Inc. (ACVA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:45PM	ACV Auctions (NASDAQ:ACVA) Beats Q4 Sales Targets But Stock Drops (StockStory)
04:05PM	ACV Announces Fourth Quarter and Full-Year 2024 Results (GlobeNewswire)
04:36AM	ACV Auctions Inc (ACVA) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-18-25 08:01AM	ACV Auctions (ACVA) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
Feb-12-25 04:01AM	Spotting Winners: eHealth (NASDAQ:EHTH) And Online Marketplace Stocks In Q3 (StockStory)
04:01AM	Online Marketplace Stocks Q3 Highlights: ACV Auctions (NASDAQ:ACVA) (StockStory)

ACV Auctions, Inc. provides a vibrant digital marketplace for wholesale vehicle transactions and data services, which offers transparent and accurate vehicle information to its customers. Its platform includes Digital Marketplace, Remarketing Centers, Data Services, and Data and Technology. The Digital Marketplace connects buyers and sellers of wholesale vehicles in an intuitive and efficient manner. The Remarketing Centers provide an additional channel to provide dealers and commercial partners with auction services. The Data Services platform offers insights into the condition and value of used vehicles for transactions both on and off its marketplace and helps dealers, their end consumers, and commercial partners make more informed decisions to transact with confidence and efficiency. The Data and Technology platform underpins everything it does, and powers its vehicle inspections, comprehensive vehicle intelligence reports, digital marketplace and operations automation platform. The company was founded by Joseph Neiman, Daniel Magnuszewsk, and Jack Greco in December 2014 and is headquartered in Buffalo, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chamoun George	Chief Executive Officer	Feb 09 '26	Buy	7.30	16,892	123,312	2,928,705	Feb 10 04:48 PM
Chamoun George	Chief Executive Officer	Jan 30 '26	Option Exercise	0.14	313,430	43,880	2,911,813	Feb 02 04:59 PM
Peer Andrew	VP, Corporate Controller & CAO	Jan 15 '26	Option Exercise	2.44	1,750	4,270	74,223	Jan 16 04:12 PM
Peer Andrew	VP, Corporate Controller & CAO	Jan 15 '26	Sale	8.85	1,750	15,488	72,473	Jan 16 04:12 PM
ANDREW PEER	Officer	Jan 15 '26	Proposed Sale	8.84	5,250	46,410		Jan 15 04:26 PM
Chamoun George	Chief Executive Officer	Jan 12 '26	Buy	8.81	14,286	125,860	2,598,383	Jan 13 04:21 PM
Chamoun George	Chief Executive Officer	Dec 15 '25	Buy	7.97	31,172	248,441	2,618,714	Dec 17 04:51 PM
Peer Andrew	VP, Corporate Controller & CAO	Dec 15 '25	Option Exercise	2.44	1,750	4,270	56,238	Dec 17 04:49 PM
Peer Andrew	VP, Corporate Controller & CAO	Dec 15 '25	Sale	8.03	1,750	14,052	55,554	Dec 17 04:49 PM
ANDREW PEER	Director	Dec 15 '25	Proposed Sale	7.99	1,750	13,982		Dec 15 04:15 PM
Peer Andrew	VP, Corporate Controller & CAO	Dec 01 '25	Option Exercise	2.00	1,750	3,500	56,238	Dec 02 04:06 PM
Peer Andrew	VP, Corporate Controller & CAO	Dec 01 '25	Sale	8.00	1,750	14,000	54,488	Dec 02 04:06 PM
ANDREW PEER	Officer	Dec 01 '25	Proposed Sale	7.85	1,750	13,738		Dec 01 04:18 PM
Castillo Kirsten	Director	Nov 14 '25	Buy	6.26	15,000	93,900	34,107	Nov 18 04:16 PM
Castillo Kirsten	Director	Nov 17 '25	Buy	6.27	5,000	31,350	39,107	Nov 18 04:16 PM
Hirsch Brian	Director	Nov 14 '25	Buy	6.21	80,571	500,346	99,678	Nov 14 05:35 PM
GOODMAN ROBERT P	Director	Nov 10 '25	Buy	5.61	912,408	5,118,609	912,408	Nov 12 08:48 PM
Peer Andrew	VP, Corporate Controller & CAO	Oct 15 '25	Option Exercise	2.00	1,750	3,500	56,238	Oct 16 04:56 PM
Peer Andrew	VP, Corporate Controller & CAO	Oct 15 '25	Sale	8.84	1,750	15,470	54,488	Oct 16 04:56 PM
ANDREW PEER	Officer	Oct 15 '25	Proposed Sale	8.81	1,750	15,418		Oct 15 04:29 PM
Peer Andrew	VP, Corporate Controller & CAO	Sep 15 '25	Option Exercise	2.00	1,750	3,500	58,500	Sep 16 04:08 PM
Peer Andrew	VP, Corporate Controller & CAO	Sep 15 '25	Sale	10.11	1,750	17,692	56,750	Sep 16 04:08 PM
ANDREW PEER	Officer	Sep 15 '25	Proposed Sale	10.01	1,750	17,518		Sep 15 04:25 PM
Anderson Craig Eric	CCDSO	Jul 22 '25	Sale	15.04	15,000	225,600	340,799	Jul 24 04:20 PM
CRAIG ANDERSON	Officer	Jul 22 '25	Proposed Sale	14.95	15,000	224,250		Jul 22 04:10 PM
Waterman Michael	Chief Sales Officer	Jul 08 '25	Option Exercise	0.14	21,429	3,000	414,296	Jul 09 04:43 PM
Waterman Michael	Chief Sales Officer	Jul 08 '25	Sale	16.05	34,339	551,141	379,957	Jul 09 04:43 PM
MICHAEL G WATERMAN	Officer	Jul 08 '25	Proposed Sale	16.10	77,196	1,242,856		Jul 08 04:22 PM
Chamoun George	Chief Executive Officer	Jun 10 '25	Sale	16.73	207,578	3,472,780	2,888,494	Jun 12 04:41 PM
Chamoun George	Chief Executive Officer	Jun 11 '25	Sale	16.92	142,422	2,409,780	2,746,072	Jun 12 04:41 PM
Waterman Michael	Chief Sales Officer	Jun 10 '25	Option Exercise	0.14	21,428	3,000	427,781	Jun 12 04:39 PM
Waterman Michael	Chief Sales Officer	Jun 10 '25	Sale	16.75	22,171	371,364	405,610	Jun 12 04:39 PM
KAMERICK EILEEN A	Director	Jun 10 '25	Sale	16.70	9,239	154,291	9,868	Jun 12 04:33 PM
GEORGE G CHAMOUN	Director	Jun 10 '25	Proposed Sale	16.69	350,000	5,841,500		Jun 10 04:21 PM
MICHAEL G WATERMAN	Officer	Jun 10 '25	Proposed Sale	16.69	22,171	370,034		Jun 10 04:21 PM
EILEEN A KAMERICK	Director	Jun 10 '25	Proposed Sale	16.70	9,239	154,306		Jun 10 04:21 PM
Waterman Michael	Chief Sales Officer	May 13 '25	Option Exercise	0.07	200,000	13,640	689,878	May 15 04:28 PM
Waterman Michael	Chief Sales Officer	May 13 '25	Sale	17.00	223,330	3,796,610	466,548	May 15 04:28 PM
MICHAEL G WATERMAN	Officer	May 13 '25	Proposed Sale	16.80	223,330	3,751,944		May 13 04:23 PM
Peer Andrew	VP, Corporate Controller & CAO	May 12 '25	Sale	17.18	10,261	176,284	60,384	May 12 04:11 PM
Peer Andrew	VP, Corporate Controller & CAO	May 08 '25	Sale	17.00	2,666	45,322	70,645	May 12 04:11 PM
ANDREW PEER	Officer	May 08 '25	Proposed Sale	15.71	12,927	203,083		May 08 04:21 PM
Waterman Michael	Chief Sales Officer	Mar 25 '25	Option Exercise	0.06	100,000	6,000	443,551	Mar 27 04:14 PM
Waterman Michael	Chief Sales Officer	Mar 25 '25	Sale	16.10	115,987	1,867,391	327,564	Mar 27 04:14 PM
MICHAEL WATERMAN	Officer	Mar 25 '25	Proposed Sale	16.01	115,987	1,856,952		Mar 25 04:19 PM
Chamoun George	Chief Executive Officer	Mar 20 '25	Sale	15.34	348,249	5,342,140	2,821,193	Mar 21 04:27 PM
Chamoun George	Chief Executive Officer	Mar 19 '25	Sale	15.00	1,751	26,265	3,169,442	Mar 21 04:27 PM
GEORGE G CHAMOUN	Director	Mar 19 '25	Proposed Sale	14.10	350,000	4,935,000		Mar 19 04:24 PM
ZERELLA WILLIAM	Chief Financial Officer	Mar 11 '25	Sale	13.53	15,000	202,950	766,266	Mar 13 04:12 PM
Chamoun George	Chief Executive Officer	Mar 07 '25	Option Exercise	0.14	300,000	42,000	2,901,048	Mar 11 04:27 PM
Chamoun George	Chief Executive Officer	Mar 10 '25	Option Exercise	0.14	250,000	35,000	3,171,193	Mar 11 04:27 PM
Chamoun George	Chief Executive Officer	Feb 21 '25	Option Exercise	0.14	450,000	63,000	2,301,048	Feb 25 04:17 PM

OCGN

Ocugen Inc

ACVA

ACV Auctions Inc

Upgrade your FINVIZ experience